Emergence of resistance to fosfomycin used as adjunct therapy in KPC klebsiella pneumoniae bacteraemia: Report of three cases

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2777-2779

  Karageorgopoulos, Drosos E ^a   Miriagou, Vivi ^b   Tzouvelekis, Leonidas S ^a   Spyridopoulou, Kalliopi ^a   Daikos, George L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Antibiotic combinations; Bloodstream infections; Carbapenemases; Enterobacteriaceae

Indexed keywords

ANTINEOPLASTIC AGENT; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; COLISTIN; FOSFOMYCIN; GENTAMICIN; MEROPENEM; TIGECYCLINE;

ABSCESS; ABSCESS DRAINAGE; ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BLOOD CULTURE; CANCER PATIENT; CASE REPORT; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LETTER; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84867608673     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks270     Document Type: Letter

References (6)

1. Michalopoulos A, Virtzili S, Rafailidis P et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6.
2. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
3. Giakkoupi P, Papagiannitsis CC, Miriagou V et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J Antimicrob Chemother 2011; 66: 1510-3.
4. Nilsson A, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-8.
5. Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55: 2395-7.
6. Loli A, Tzouvelekis LS, Tzelepi E et al. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1. J Antimicrob Chemother 2006; 58: 669-72.